Antiviral Drugs Market Size, Share, Growth and Forecast, 2025-2035

HIV care and long-acting prevention anchor antiviral demand

The global antiviral drugs market was valued at USD 77.93 billion in 2025 and is projected to increase from USD 81.72 billion in 2026 to USD 125.26 billion by 2035, registering a CAGR of 4.86% during 2026–2035. Demand rests on lifelong antiretroviral therapy for HIV, chronic hepatitis B and C treatment, seasonal influenza courses and herpes suppression, which together keep prescriptions moving every year. North America held the largest regional share, 47.0% in 2025, because branded HIV regimens and prevention products sell at the highest net prices there. Asia Pacific is the fastest-growing region at 6.08% a year, as hepatitis screening widens and generic makers in India expand supply. The commercial picture changed in 2025 and 2026, when U.S. regulators cleared a twice-yearly HIV prevention injection, a two-drug HIV tablet without an integrase inhibitor and the first oral pill for COVID-19 prevention after exposure. As a result, value is tilting toward long-acting and preventive antivirals.

Which antiviral medicines and buyers does this analysis cover?

The analysis counts prescription antivirals used to treat or prevent HIV, hepatitis B and C, herpes viruses, influenza, COVID-19 and other viral infections in people, valued at manufacturer selling prices. Retail and specialty pharmacies dispense most oral regimens against prescriptions, while hospitals buy intravenous agents and long-acting injectables through formularies and tenders. HIV medicines are counted for both treatment and pre-exposure prophylaxis, because the same originators and generic suppliers serve both uses.

Vaccines, monoclonal antibodies used only for passive immunization and diagnostic tests sit outside the scope of this analysis. The value chain runs from active ingredient producers in India and China through originator brands and generic formulators to wholesalers, pharmacies, national programs and donors that fund treatment in lower-income countries.

Combination regimens lead while hepatitis care gains pace

Why do combination regimens hold the largest therapy share?

Based on type of therapy, the market is categorized into monotherapy and combination therapy. Combination Therapy led with a 62.0% share of 2025 value, because HIV and hepatitis C are treated with single tablets that combine two or more agents. Monotherapy grows fastest at 5.23% a year, since twice-yearly prevention injections and single-agent influenza and COVID-19 pills reach new patients. This shift keeps both formats relevant for originators and generic suppliers.

How is the mechanism mix moving beyond older drug classes?

Based on mechanism of action, the market is categorized into fusion inhibitors, DNA polymerase inhibitors, protease inhibitors, reverse transcriptase inhibitors and others. Reverse Transcriptase Inhibitors led with a 40.0% share of 2025 value, because nucleoside and non-nucleoside agents form the backbone of most HIV and hepatitis B regimens. Others grow fastest at 5.76% a year, a group that includes integrase inhibitors, capsid inhibitors and endonuclease inhibitors. Fusion inhibitors remain a small niche for heavily treated HIV patients.

Which viral infections account for the most spending?

Based on indication, the market is categorized into HIV, hepatitis, herpes, influenza and others. HIV led with a 58.0% share of 2025 value, because patients take antiretroviral therapy every day for life. Hepatitis grows fastest at 5.32% a year, as screening programs find more people with chronic hepatitis B and C. In turn, demand for hepatitis C treatment rises in Asia and Africa, where most undiagnosed patients live.

Where do patients and programs obtain these medicines?

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, online pharmacy and others. Retail Pharmacy led with a 46.0% share of 2025 value, because oral HIV, hepatitis and herpes medicines are refilled in the community. Online Pharmacy grows fastest at 6.45% a year, as mail-order HIV refills and telehealth prescribing for influenza move volume online. Hospital pharmacies keep a large share through intravenous agents and clinic-administered injections.

HIV treatment gaps and hepatitis burden lift demand

Why does the HIV treatment gap keep demand rising?

HIV forms the largest recurring demand base, because people living with HIV take antiretroviral medicines every day for life. According to the UNAIDS global HIV fact sheet, 41.0 million people were living with HIV in 2025 and 32.1 million were accessing antiretroviral therapy. This leaves close to nine million people outside treatment, and national programs and donors aim to close that gap. As a result, generic fixed-dose combinations expand volume in Africa and Asia, while branded regimens hold value in high-income countries.

How does the hepatitis burden widen the treatment pool?

Chronic viral hepatitis is a large and underserved pool of patients, because most people with the disease have never been diagnosed. The World Health Organization reported in April 2024 that 254 million people lived with hepatitis B and 50 million with hepatitis C in 2022, and that viral hepatitis causes 1.3 million deaths a year. Only 3% of people with chronic hepatitis B had received antiviral therapy by the end of 2022. This gap means that each expansion of screening adds patients who need long-term or curative treatment.

Download Free Sample

How is long-acting prevention adding new patients?

Prevention is turning healthy people at risk into antiviral users, which widens the market beyond those already infected. In June 2025, the U.S. Food and Drug Administration approved Gilead's Yeztugo (lenacapavir) as a twice-yearly injection for HIV pre-exposure prophylaxis in adults and adolescents. The World Health Organization then recommended injectable lenacapavir as an additional prevention option in July 2025. Because each dose protects for six months, adherence improves and programs can reach people who struggle with daily pills.

Why do respiratory viruses keep seasonal demand steady?

Respiratory viruses create recurring seasonal demand, because influenza and COVID-19 return every winter in both hemispheres. Older adults, people with chronic illness and households with exposed contacts account for most prescriptions written in clinics and pharmacies. In May 2026, U.S. regulators approved Shionogi's Xocova (ensitrelvir) as the first oral option for COVID-19 prevention after exposure in people aged 12 and older. In turn, demand for influenza therapeutics and COVID-19 pills stays tied to season severity.

Twice-yearly dosing and two-drug regimens reshape therapy

Is twice-yearly dosing shifting the HIV prevention mix?

Long-acting dosing is the clearest shift in antiviral prescribing, because it removes the daily pill burden that limits adherence. The rise of twice-yearly lenacapavir moves value toward clinic-administered injections and specialty pharmacies. This shift also changes how programs buy medicines, since two injections a year replace monthly pill refills for people on pre-exposure prophylaxis. As a result, hospital and clinic channels gain share in prevention, while retail pharmacies keep most daily oral treatment volume.

Are two-drug regimens emerging as a new HIV standard?

Two-drug regimens are emerging as an alternative to three-drug therapy, because fewer agents can mean fewer long-term side effects. In April 2026, the U.S. Food and Drug Administration approved Merck's Idvynso (doravirine and islatravir) as a once-daily tablet for adults with virologically suppressed HIV-1. It is the first approved regimen that contains neither an integrase inhibitor nor tenofovir. This rise of new combinations gives prescribers more choice for switching patients, and it intensifies competition among HIV originators.

Download Free Sample

Where can generic makers capture growth in HIV prevention access?

Licensed generic lenacapavir is an opportunity for Indian and Egyptian manufacturers, because donors buy prevention products in very large volumes. In October 2024, Gilead signed royalty-free licenses with six generic makers, including Dr. Reddy's Laboratories, to supply lenacapavir in 120 countries. This model gives Indian producers, which already supply a large share of donor-funded HIV-1 therapies, a route into long-acting products. In turn, suppliers that win Global Fund and national tenders can offset thin unit margins with multi-year prevention volumes.

Can functional cure approaches open a hepatitis B opportunity?

Hepatitis B offers an opening for companies that can move beyond lifelong suppression toward a functional cure. In March 2026, the European Medicines Agency accepted GSK's marketing application for bepirovirsen, an antisense medicine for chronic hepatitis B, after two phase III trials. Because current nucleoside analogs require years of daily use, a finite-duration therapy could command premium prices in Asia, Europe and North America. As a result, hepatitis can grow faster than the overall market if such products reach approval and reimbursement.

Generic erosion and diagnosis gaps restrain value growth

How does generic price erosion limit value growth?

Generic tenofovir, lamivudine, dolutegravir and sofosbuvir bought by public programs cost a small fraction of originator prices, because many manufacturers bid for the same public contracts. Indian producers such as Cipla, Aurobindo Pharma and Sun Pharmaceutical supply low-cost versions to public programs in Africa, Asia and Latin America. This pressure means that rising patient numbers do not translate into proportional value growth. As a result, originators offset erosion with long-acting formulations, new combinations and pediatric versions that carry better margins.

Why do diagnosis gaps hold back hepatitis treatment?

Low diagnosis rates are the main barrier in hepatitis, because patients who are never tested never receive treatment. The World Health Organization found that only 13% of people with chronic hepatitis B and 36% of people with hepatitis C had been diagnosed by the end of 2022. Treatment coverage was lower still, at 3% for hepatitis B and 20% for hepatitis C. In turn, growth depends on screening budgets and simplified care models in high-burden countries.

Does seasonal volatility make respiratory sales unpredictable?

Seasonal volatility makes influenza and COVID-19 sales hard to forecast, because demand rises and falls with the severity of each winter. A mild season can leave pharmacies and government stockpiles with excess inventory, which depresses orders in the following year. Pfizer and Shionogi face this pattern in their respiratory portfolios, while governments adjust stockpiling budgets after each pandemic review. However, steady prevention use among high-risk groups provides a partial floor under respiratory antiviral demand.

Why does drug resistance complicate long-term therapy?

Drug resistance complicates long-term therapy, because viruses that replicate under incomplete suppression can escape older agents. Patients who miss doses or receive weak regimens may need costlier second-line or salvage treatment, which strains program budgets in lower-income countries. This risk keeps resistance testing and adherence support central to HIV and hepatitis B care. As a result, prescribers favor high-barrier regimens, and developers must show activity against resistant strains to win formulary listings.

North America leads as Asia Pacific expands access

Why does North America hold the largest regional share?

North America held a 47.0% share of 2025 value and grows at 4.48% a year through 2035. The United States drives this position, because branded HIV regimens, long-acting prevention and respiratory antivirals sell at the highest net prices in the world. Recent U.S. approvals for HIV prevention, two-drug HIV therapy and COVID-19 prevention reach this region first. However, generic entry for older HIV agents and pharmacy benefit managers pushing for lower net prices hold regional growth under the worldwide pace.

How fast is Asia Pacific catching up?

Asia Pacific held a 19.0% share of 2025 value and is the fastest-growing region at 6.08% a year. China and India carry the largest hepatitis B and C burdens in the world, and expanding insurance coverage lifts the number of patients treated. India is also a leading supplier of generic antiretrovirals and hepatitis medicines, giving Cipla, Aurobindo Pharma and Sun Pharmaceutical scale at home and abroad. Japan adds a high-value market for influenza and COVID-19 pills developed by Shionogi.

Download Free Sample

What shapes demand across Europe?

Europe held a 24.0% share of 2025 value and grows at 4.28% a year, the slowest pace of the five regions. Centralized pricing and tenders hold down prices across Germany, France, Italy and Spain, and most diagnosed HIV patients in Western Europe are already on therapy. However, hepatitis C elimination programs and long-acting HIV injections add new value. A potential hepatitis B functional cure would also reach European patients early, given the regulatory review under way since March 2026.

Where is Latin America adding demand?

Latin America held a 5.0% share of 2025 value and grows at 5.48% a year through 2035. Brazil and Mexico lead regional demand, supported by public HIV programs that buy antiretrovirals centrally and by hepatitis C treatment campaigns. Budget limits slow the adoption of premium long-acting products, so generic supply dominates volumes in most countries.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 5.0% share of 2025 value and grows at 5.68% a year through 2035. Sub-Saharan Africa carries the largest HIV burden in the world, but donor-funded generics keep spending per patient low. Generic lenacapavir supply under the 2024 licenses is expected to widen prevention access across the region.

Download Free Sample

Approvals and licensing deals redraw viral disease care

Capsid inhibitors and new mechanisms shape the pipeline

• Capsid inhibitors such as lenacapavir disrupt several stages of the HIV life cycle and allow dosing every six months, which reduces adherence gaps.
• Nucleoside reverse transcriptase translocation inhibitors such as islatravir block viral DNA synthesis through a distinct mechanism, which enables new two-drug combinations.
• Antisense oligonucleotides such as bepirovirsen target hepatitis B viral RNA, which aims to suppress surface antigen and achieve a functional cure after finite treatment.
• Protease and endonuclease inhibitors used in oral COVID-19 and influenza pills stop viral replication early, which supports treatment and prevention after exposure.

HIV originators and Indian generic makers split the field

Competition splits between originators that hold patented HIV, hepatitis and respiratory franchises and generic manufacturers that supply most volume. Gilead Sciences leads HIV treatment and prevention, while GlaxoSmithKline competes through ViiV Healthcare and its hepatitis B pipeline. Merck & Co. is rebuilding its HIV position with two-drug regimens, and Pfizer and Shionogi hold leading oral COVID-19 and influenza products. Sanofi maintains a presence in viral disease care, while Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories and Sun Pharmaceutical compete on price in generic antiretrovirals and hepatitis medicines. These Indian producers increasingly win donor tenders in Africa and Asia. Originators differentiate through dosing intervals, resistance barriers and fewer agents per regimen, while generic makers win on cost and tender reliability. However, patent expiries on older HIV agents keep pressure on originators to move patients to newer regimens.

Companies profiled and their roles in this market

Value moves toward long-acting and curative approaches

Credence Research's view is that value in antivirals will concentrate in two places through 2035, long-acting HIV medicines and finite-duration hepatitis B therapy. Both segments command premium prices, because they solve problems that daily generic pills cannot solve, namely poor adherence and lifelong dependence on suppression. While the overall market grows at 4.86% a year, generic antiretrovirals will keep growing in volume across Asia Pacific and Africa, but their value share will drift lower as tender prices fall. The originators best placed for 2035 are those whose six-month or finite-duration products also reach donor programs through licensing.

How Credence Research sized antiviral medicine spending

Antiviral values in this edition use 2025 as the base year and 2026 to 2035 as the forecast window. Market values come from the Credence Research model, which adds up spending by type of therapy, mechanism of action, indication and distribution channel. Regional and segment splits are Credence Research estimates informed by regulator approvals, World Health Organization and UNAIDS surveillance data, and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Viral disease treatment spending outlook to 2035

By 2035, the antiviral drugs market is projected to reach USD 125.26 billion, with growth tilted toward HIV prevention, hepatitis and respiratory virus prevention. Long-acting injectables should take a larger share of HIV spending as prevention programs scale in Africa, Asia and Latin America. Hepatitis treatment should gain as screening expands and new approaches aim for a functional cure. Asia Pacific should add the largest number of new patients, while North America keeps the highest value per patient. As a result, the strongest positions will belong to companies that pair long-acting or curative products with low-cost supply for public programs.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.